![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
517 episodes
![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
The Bio Report Levine Media Group
-
- Science
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
-
Reshaping Clinical Trial Designs with Real-World Data
Neal Meropol, head of research oncology at Flatiron Health, discusses how real-world evidence can inform better clinical trial designs and accelerate drug development, how Flatiron works with its clients, and a recent study he was involved in that suggest drug developers who want to increase the diversity of clinical trials participants should consider broadening their inclusion criteria.
-
Using Generative AI to Produce Precise Gene Editors
Hilary Eaton, chief business officer for Profluent, discusses the company’s generative AI engine to produce CRISPR enzymes, its business model, and why its platform has the potential to create other protein therapeutics of varying modalities.
-
Enabling the Nervous System to Repair Itself
Mike Kelly, CEO of NervGen Pharma, discusses the potential for using therapies designed to allow the nervous system to repair itself, how the company’s lead experimental candidate for spinal cord injury works, and why the same approach holds promise in treating a range of neurodegenerative diseases.
-
Overcoming Barriers to Delivering Large Molecules to the Brain
John Dunlop, chief scientific officer of Aliada, discusses its platform technology, its origins at Johnson & Johnson’s Janssen, and the company’s partnering strategy for leveraging the technology.
-
Developing Complex Therapies to Tackle Complex Diseases
Sam Murphy, CEO of SalubrisBio, discusses the challenges of pursuing complex diseases with complex therapies, its pipeline, and how its China-based parent has provided it financial freedom from the vagaries of the capital markets.
-
How Solving a Problem with Genetic Medicines May Solve Another with Infectious Diseases
John Lewis, founder and CEO of Aegis Life, discusses the global need to address infectious diseases, the company’s platform technology, and how it is leveraging that to address the barriers to the delivery of vaccines and antibody therapies in developing economies.